{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T16:49:58Z","timestamp":1770569398532,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.yrtph.2019.104540","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T02:55:40Z","timestamp":1574218540000},"page":"104540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Oral repeated-dose toxicity studies of BIA 10\u20132474 in Wistar rat"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-3179","authenticated-orcid":false,"given":"A. Wallace","family":"Hayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry F.","family":"Hardisty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2019.104540_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.yrtph.2019.104540_bib2","first-page":"3063","article-title":"Pharmacodynamic and ADME evaluation of FAAH inhibitor BIA 10-2474","volume":"29","author":"Bonif\u00e1cio","year":"2018","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.yrtph.2019.104540_bib3","first-page":"3063","article-title":"In-vivo selectivity profiling of BIA 10-2474 against serine hydrolases in the rat brain","volume":"29","author":"Bonif\u00e1cio","year":"2018","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.yrtph.2019.104540_bib4","series-title":"Saint-Denis","article-title":"Report by the temporary specialist scientific committee (TSSC): FAAH (fatty acid amide hydrolase),\u201d on the causes of the accident during a phase 1 clinical trial in Rennes in january 2016","author":"CSST","year":"2016"},{"key":"10.1016\/j.yrtph.2019.104540_bib5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.yrtph.2019.104540_bib6","article-title":"Preliminary safety evaluation in study BIA-10-2474-101","author":"Gama","year":"2016","journal-title":"Proc. Br. Paedodontic Soc."},{"key":"10.1016\/j.yrtph.2019.104540_bib7","article-title":"Oral repeated-dose toxicity studies of BIA 10-2474 in beagle dogs","author":"Hardisty","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib8","article-title":"Developmental and reproductive toxicity studies of BIA 10-2474","author":"Harris","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib9","article-title":"The absence of genotoxicity of a novel fatty acid amide hydrolase inhibitor BIA 10-2474","author":"Hayes","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib10","article-title":"Oral repeated-dose toxicity studies of BIA 10-2474 in CD-1 mice","author":"Hayes","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib11","article-title":"Global portrait of protein targets of metabolites of the neurotoxic compound BIA 10\u20132474","author":"Huang","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.yrtph.2019.104540_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml100190t","article-title":"Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor","volume":"2","author":"Johnson","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.yrtph.2019.104540_bib13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1021\/acsmedchemlett.5b00353","article-title":"Preclinical characterization of the FAAH inhibitor JNJ-42165279","volume":"6","author":"Keith","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.yrtph.2019.104540_bib14","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","article-title":"Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase","volume":"375","author":"Kerbrat","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2019.104540_bib15","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/cmdc.201800393","article-title":"Discovery of a potent, long-acting, and CNS-active inhibitor (BIA 10-2474) of fatty acid amide hydrolase","volume":"13","author":"Kiss","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.yrtph.2019.104540_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/CPP43217","article-title":"Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects","volume":"43","author":"Lutfullin","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2019.104540_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.yrtph.2016.05.002","article-title":"Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials","volume":"80","author":"Mead","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib18","series-title":"Simultaneous Statistical Inferences","author":"Miller","year":"1981"},{"key":"10.1016\/j.yrtph.2019.104540_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.yrtph.2019.104540_bib20","first-page":"51","article-title":"FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels","volume":"11","author":"Petrosino","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.yrtph.2019.104540_bib21","article-title":"Tolerability, pharmacokinetic and pharmacodynamic profile of BIA 10-2474 in healthy volunteers following multiple ascending doses","author":"Rocha","year":"2016","journal-title":"Proc. Br. Paedodontic Soc."},{"key":"10.1016\/j.yrtph.2019.104540_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s002280050413","article-title":"Adverse events in phase-I studies: a report in 1015 healthy volunteers","volume":"54","author":"Sibille","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lfs.2018.04.054","article-title":"Enhanced endocannabinoid tone as a potential target of pharmacotherapy","volume":"204","author":"Toczek","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.yrtph.2019.104540_bib24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.yrtph.2019.104540_bib25","article-title":"Oral repeated-dose toxicity studies of BIA 10-2474 in Cynomolgus monkeys","author":"Weber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104540_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5414\/CPP48563","article-title":"The safety of healthy volunteers in First-in-Man trials - an analysis of studies conducted at the Bayer in-house ward from 2000 to 2005","volume":"48","author":"Wensing","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019303046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019303046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:29:07Z","timestamp":1759494547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230019303046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":26,"alternative-id":["S0273230019303046"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104540","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral repeated-dose toxicity studies of BIA 10\u20132474 in Wistar rat","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104540"}}